
HRMY Stock Forecast & Price Target
HRMY Analyst Ratings
Bulls say
Harmony Biosciences Holdings Inc. is poised for significant growth, with expectations that WAKIX sales will increase from approximately $160 million in 2020 to over $700 million by 2024, driven by its safety and convenience advantages. The company has a strong pipeline of products, including pitolisant-GR, which aims to improve patient adherence by eliminating the need for dose titration, as evidenced by successful outcomes in their dosing optimization study. With multiple registrational trials set to either initiate or report results in the next 12 to 18 months, alongside a solid financial position to support internal research and development, Harmony represents a compelling growth opportunity in the neurology sector.
Bears say
Harmony Biosciences Holdings Inc. recently reported disappointing results from its pivotal Phase 3 RECONNECT trial for ZYN002, which did not meet its primary endpoint due to a higher-than-expected placebo response, raising concerns about the efficacy of this candidate. The company faces several risks that could negatively impact its revenue growth, including increased competition in the sodium oxybate market affecting WAKIX sales, a potential slowdown in new patient additions, and the uncertainty surrounding the success of ongoing clinical trials for various neurological conditions. Additionally, the potential for earlier-than-expected competition from generic pitolisant compounds further complicates the company's future revenue projections and overall market positioning.
This aggregate rating is based on analysts' research of Harmony Biosciences Holdings and is not a guaranteed prediction by Public.com or investment advice.
HRMY Analyst Forecast & Price Prediction
Start investing in HRMY
Order type
Buy in
Order amount
Est. shares
0 shares